
Huimin Bai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3383188/publications.pdf Version: 2024-02-01



HUIMIN RAI

#	Article	IF	CITATIONS
1	Clinicopathological characteristics and treatment of patients with high-grade endometrial stromal sarcoma. Medicine (United States), 2022, 101, e28490.	0.4	Ο
2	Phospholipase <scp>D1</scp> promotes cervical cancer progression by activating the <scp>RAS</scp> pathway. Journal of Cellular and Molecular Medicine, 2022, 26, 4244-4253.	1.6	4
3	Accuracy of HPV E6/E7 mRNA examination using in situ hybridization in diagnosing cervical intraepithelial lesions. Diagnostic Pathology, 2021, 16, 13.	0.9	8
4	Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes. Frontiers in Genetics, 2021, 12, 680413.	1.1	12
5	The oncological and obstetric outcomes of cervical squamous cell carcinoma at stage IA1 managed with the loop electrosurgical excision procedure. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 718-722.	0.5	Ο
6	DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway. Journal of Cellular and Molecular Medicine, 2021, 25, 9306-9318.	1.6	7
7	Potential interaction between lysophosphatidic acid and tumor-associated macrophages in ovarian carcinoma. Journal of Inflammation, 2020, 17, 23.	1.5	19
8	<p>A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles from Culture Supernatant of Human Ovarian Cancer Cell Line A2780 and Body Fluids of High-Grade Serous Carcinoma Patients</p> . Cancer Management and Research, 2020, Volume 12, 6291-6301.	0.9	7
9	Reproductive outcomes of cesarean scar pregnancies pretreated with methotrexate and uterine artery embolization prior to curettage. Taiwanese Journal of Obstetrics and Gynecology, 2020, 59, 381-386.	0.5	8
10	The Safety and Efficacy of Intra-Arterial versus Intravenous Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-7.	0.5	2
11	The Role of Lysophosphatidic Acid Receptors in Ovarian Cancer: A Minireview. Critical Reviews in Eukaryotic Gene Expression, 2020, 30, 265-272.	0.4	9
12	LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway. Cancer Cell International, 2019, 19, 201.	1.8	13
13	The clinical benefits of hormonal treatment for LG-ESS: a meta-analysis. Archives of Gynecology and Obstetrics, 2019, 300, 1167-1175.	0.8	8
14	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine, 2019, 23, 2303-2313.	1.6	103
15	<p>Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis</p> . Cancer Management and Research, 2019, Volume 11, 4005-4021.	0.9	21
16	Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Management and Research, 2019, Volume 11, 4371-4390.	0.9	77
17	The security of radical trachelectomy in the treatment of IA–IIA cervical carcinoma requires further evaluation: updated meta-analysis and trial sequential analysis. Archives of Gynecology and Obstetrics, 2019, 299, 1525-1536.	0.8	7
18	Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: a retrospective study. BMC Pregnancy and Childbirth, 2018, 18, 298.	0.9	23

Ηυιμιν Βαι

#	Article	IF	CITATIONS
19	Oncological and reproductive outcomes of adenocarcinoma in situ of the cervix managed with the loop electrosurgical excision procedure. BMC Cancer, 2018, 18, 461.	1.1	7
20	The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. Archives of Gynecology and Obstetrics, 2018, 298, 465-475.	0.8	2
21	Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Oncotarget, 2017, 8, 15136-15148.	0.8	6
22	The safety of fertility and ipsilateral ovary procedures for borderline ovarian tumors. Oncotarget, 2017, 8, 115718-115729.	0.8	15
23	Occult invasive cervical cancer after simple hysterectomy: a multi-center retrospective study of 89 cases. BMC Cancer, 2016, 16, 507.	1.1	7
24	Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. Gynecologic Oncology, 2016, 143, 526-531.	0.6	23
25	Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. Journal of Cellular and Molecular Medicine, 2016, 20, 581-593.	1.6	39
26	The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget, 2016, 7, 15566-15576.	0.8	21
27	Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma. Medicine (United States), 2015, 94, e1121.	0.4	11
28	The potential for less radical surgery in women with stage IA2–IB1 cervical cancer. International Journal of Gynecology and Obstetrics, 2015, 130, 235-240.	1.0	16
29	Characteristic and Prognostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study. PLoS ONE, 2015, 10, e0121818.	1.1	21
30	The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget, 2015, 6, 25520-25532.	0.8	81
31	Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins. OncoTargets and Therapy, 2014, 7, 1705.	1.0	25
32	Comparative study of ovarian clearÂcell carcinoma with and without endometriosis in People's Republic of China. Fertility and Sterility, 2014, 102, 1656-1662.	0.5	42
33	Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: A retrospective study of 153 cases. Gynecologic Oncology, 2014, 132, 654-660.	0.6	82